WonBiogen Co

WonBiogen Co Equity

The The Equity of WonBiogen Co (307280.KQ) as of Oct 20, 2026 is 42.73 B KRW. In the previous year, The Equity was 37.21 B KRW — a change of 14.83% (higher).

Equity

42.73 BKRW

YoY

14.83%

Last updated:

In 2025, WonBiogen Co's equity was 42.73 B KRW, a 14.83% increase from the 37.21 B KRW equity in the previous year.

The WonBiogen Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2020
6.71 B KRW
Jan 1, 2021
26.70 B KRW
Jan 1, 2022
26.87 B KRW
Jan 1, 2023
32.22 B KRW
Jan 1, 2024
37.21 B KRW
Jan 1, 2025
42.73 B KRW
The WonBiogen Co Equity history
YEAREquityYoY
42.73 BKRW+14.83%
37.21 BKRW+15.47%
32.22 BKRW+19.93%
26.87 BKRW+0.61%
26.70 BKRW+298.13%
6.71 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

WonBiogen Co Stock analysis

What does WonBiogen Co do? WonBiogen Co Ltd, based in Gumi, South Korea, operates in the Health Care sector, focusing on the research and development of biocompatible medical materials. The company, listed on 5 December 2018, provides medical products such as wound dressings for lower leg ulcers, pressure ulcers, and surgical wounds, as well as absorbent dressings and fixation bands for bandages and catheters. WonBiogen Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing WonBiogen Co's Equity

WonBiogen Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding WonBiogen Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating WonBiogen Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

WonBiogen Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in WonBiogen Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about WonBiogen Co stock

The Equity of WonBiogen Co is 42.73 B KRW in 2025.

The Equity of WonBiogen Co changed from 37.21 B KRW to 42.73 B KRW, representing a 14.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity WonBiogen Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's WonBiogen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — WonBiogen Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — WonBiogen Co